International consensus statement on allergy and rhinology: Allergic rhinitis–2023
Background In the 5 years that have passed since the publication of the 2018 International
Consensus Statement on Allergy and Rhinology: Allergic Rhinitis (ICAR‐Allergic Rhinitis …
Consensus Statement on Allergy and Rhinology: Allergic Rhinitis (ICAR‐Allergic Rhinitis …
Epidemiology and management of interstitial lung disease in ANCA-associated vasculitis
Antineutrophil cytoplasmic antibodies (ANCA)-associated vasculitis (AAV) is a group of
systemic vasculitides that predominantly affect small vessels, including granulomatosis with …
systemic vasculitides that predominantly affect small vessels, including granulomatosis with …
Lung involvement in ANCA-associated vasculitis
G Sacoto, S Boukhlal, U Specks, LF Flores-Suárez… - La Presse Médicale, 2020 - Elsevier
Lung involvement is one of the most common clinical features in ANCA-associated
vasculitides (AAV), including granulomatosis with polyangiitis (GPA), microscopic …
vasculitides (AAV), including granulomatosis with polyangiitis (GPA), microscopic …
T-regulatory cells in tumor progression and therapy
Regulatory T cells (Tregs) are important members of the immune system regulating the host
responses to infection and neoplasms. Tregs prevent autoimmune disorders by protecting …
responses to infection and neoplasms. Tregs prevent autoimmune disorders by protecting …
Monitoring disease activity in antineutrophil antibody‐associated vasculitis
FG Scurt, V Hirschfeld, L Schubert… - Scandinavian …, 2023 - Wiley Online Library
Antineutrophil cytoplasm antibody (ANCA)–associated vasculitis (AAV) comprises a group of
multisystem disorders with alternating periods of relapse and remission. Beyond that, a …
multisystem disorders with alternating periods of relapse and remission. Beyond that, a …
Old known and possible new biomarkers of ANCA-associated vasculitis
FG Scurt, K Bose, B Hammoud, S Brandt… - Journal of …, 2022 - Elsevier
Antineutrophil cytoplasm antibody (ANCA)-associated vasculitis (AAV) comprises a group of
multisystem disorders involving severe, systemic, small-vessel vasculitis with short-and long …
multisystem disorders involving severe, systemic, small-vessel vasculitis with short-and long …
Ocular manifestations of granulomatosis with polyangiitis: report from a tertiary eye care center
I Korkmaz, O Barut Selver, S Egrilmez, A Yagci… - International …, 2024 - Springer
Purpose To report demographic characteristics and ophthalmological manifestations of
patients with granulomatosis with polyangiitis (GPA) in a tertiary eye care center in Turkey …
patients with granulomatosis with polyangiitis (GPA) in a tertiary eye care center in Turkey …
[HTML][HTML] Granulomatous polyangiitis with renal involvement: a case report and review of literature
T Koritala, TO Mene-Afejuku, M Schaefer, L Dondapati… - Cureus, 2021 - ncbi.nlm.nih.gov
Granulomatosis with polyangiitis (GPA), formerly named Wegner's granulomatosis is an
antineutrophilic cytoplasmic antibody (ANCA) associated vasculitis of the small vessels …
antineutrophilic cytoplasmic antibody (ANCA) associated vasculitis of the small vessels …
Cranial base manifestations of granulomatosis with polyangiitis
PT Kiessling, JP Marinelli, PA Peters… - … –Head and Neck …, 2020 - journals.sagepub.com
Objective Although granulomatosis with polyangiitis (GPA; Wegener's granulomatosis) is
classically characterized by systemic disease involving the kidneys and airway …
classically characterized by systemic disease involving the kidneys and airway …
[HTML][HTML] Patients treated with rituximab are poorly screened for hepatitis B infection: Data from a low-incidence country
SM Brakenhoff, R Hoekstra, P Honkoop… - European Journal of …, 2023 - Elsevier
Abstract Background & Aims Patients with chronic or resolved hepatitis B are at risk of
hepatitis B reactivation (HBVr) when treated with high-risk immunosuppressive therapy such …
hepatitis B reactivation (HBVr) when treated with high-risk immunosuppressive therapy such …